Merck & Co., Inc. (NYSE:MRK) Downgraded to “Sector Perform” Rating by Royal Bank Of Canada

Merck & Co., Inc. (NYSE:MRK) was downgraded by investment analysts at Royal Bank Of Canada from an “outperform” rating to a “sector perform” rating in a report issued on Thursday. They currently have a $150.00 price objective on the stock. Royal Bank Of Canada’s price target suggests a potential downside of 1.45% from the company’s current price.

Several other research firms have also recently weighed in on MRK. BMO Capital Markets boosted their target price on Merck & Co., Inc. from $135.00 to $142.00 and gave the stock an “outperform” rating in a research note on Monday, July 13th. Barclays raised their price objective on Merck & Co., Inc. from $140.00 to $150.00 and gave the stock an “overweight” rating in a report on Wednesday, July 29th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 target price on the stock in a report on Wednesday, August 12th. Weiss Ratings downgraded Merck & Co., Inc. from a “hold (c)” rating to a “hold (c-)” rating in a research note on Tuesday, August 11th. Finally, Cantor Fitzgerald restated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a research report on Monday, July 6th. Fifteen equities research analysts have rated the stock with a Buy rating and eight have assigned a Hold rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $139.20.

Merck & Co., Inc. Price Performance

Shares of MRK opened at $152.21 on Thursday. The firm has a market capitalization of $375.53 billion, a price-to-earnings ratio of 121.77, a PEG ratio of 5.83 and a beta of 0.19. The firm’s fifty day simple moving average is $126.86 and its 200-day simple moving average is $120.74. Merck & Co., Inc. has a twelve month low of $77.58 and a twelve month high of $153.50. The company has a current ratio of 1.32, a quick ratio of 1.10 and a debt-to-equity ratio of 1.22.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, August 4th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to the consensus estimate of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The company’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $2.13 earnings per share. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. Equities analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Insider Activity

In other news, EVP Chirfi Guindo sold 15,000 shares of Merck & Co., Inc. stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $131.00, for a total transaction of $1,965,000.00. Following the completion of the transaction, the executive vice president owned 46,613 shares of the company’s stock, valued at $6,106,303. The trade was a 24.35% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, EVP Richard R. Deluca sold 20,784 shares of the business’s stock in a transaction dated Monday, August 10th. The stock was sold at an average price of $130.43, for a total transaction of $2,710,857.12. Following the completion of the sale, the executive vice president owned 134,703 shares in the company, valued at $17,569,312.29. This represents a 13.37% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock valued at $29,977,783 in the last 90 days. Insiders own 0.17% of the company’s stock.

Hedge Funds Weigh In On Merck & Co., Inc.

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in MRK. Susquehanna Fundamental Investments LLC purchased a new position in shares of Merck & Co., Inc. during the 2nd quarter worth approximately $11,470,000. Benjamin Edwards Inc. lifted its stake in Merck & Co., Inc. by 36.3% in the 2nd quarter. Benjamin Edwards Inc. now owns 224,529 shares of the company’s stock valued at $28,854,000 after buying an additional 59,854 shares in the last quarter. Alyeska Investment Group L.P. lifted its stake in Merck & Co., Inc. by 7.6% in the 2nd quarter. Alyeska Investment Group L.P. now owns 2,480,590 shares of the company’s stock valued at $318,756,000 after buying an additional 175,016 shares in the last quarter. Meiji Yasuda Life Insurance Co grew its holdings in Merck & Co., Inc. by 4.1% during the 2nd quarter. Meiji Yasuda Life Insurance Co now owns 14,833 shares of the company’s stock valued at $1,906,000 after buying an additional 590 shares during the last quarter. Finally, Thornburg Investment Management Inc. grew its holdings in Merck & Co., Inc. by 1.6% during the 2nd quarter. Thornburg Investment Management Inc. now owns 3,787,976 shares of the company’s stock valued at $486,755,000 after buying an additional 59,303 shares during the last quarter. Institutional investors and hedge funds own 76.07% of the company’s stock.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: The combination of Moderna’s individualized vaccine, intismeran, and Keytruda significantly extended the time high-risk melanoma patients remained free of recurrence and reduced the risk of cancer spreading compared with Keytruda alone. The result is viewed as the first positive late-stage validation of a personalized mRNA cancer vaccine. Merck, Moderna say melanoma skin cancer vaccine meets goals in large trial
• Positive Sentiment: The data strengthen Merck’s oncology pipeline and could help offset concerns about the expected expiration of Keytruda’s patent later this decade. The companies are also studying similar vaccine approaches in lung, pancreatic, breast and other cancers, potentially expanding the commercial opportunity if regulators approve the treatment; approval is targeted for 2027. Moderna, Merck breakthrough could usher in wave of cancer vaccines
• Positive Sentiment: Investor enthusiasm was reflected in unusually heavy options activity, with 68,587 Merck call options purchased—about 188% above typical daily volume—suggesting increased bullish speculation, though options activity is not a fundamental performance measure.
• Neutral Sentiment: Broader bond-market relief supported interest-rate-sensitive equities and healthcare stocks, providing a favorable market backdrop for MRK. Stock Market Today, Aug. 19
• Negative Sentiment: Jefferies downgraded MRK from “strong buy” to “hold.” The call could limit further upside and reflects a more cautious analyst view after the stock’s strong run toward its 52-week high, although the firm’s specific rationale was not provided.

About Merck & Co., Inc.

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.